Quadrant Laboratories: (“QLabs”)
A new standard of molecular diagnostics, QLabs engages in the research, development and commercialization of molecular diagnostics for certain public health priorities, including Autism Spectrum Disorder (“ASD”), mild-traumatic brain injuries (“mTBI”), Parkinson’s Disease (“PD”) and others. QLabs owns and operates (i) a research and development laboratory with expertise in AI/machine-learning-based discoveries derived from patient phenotypic and genetic/multi-omic next generation sequencing data, and (ii) a 50-state CLIA/CLEP clinical laboratory. QLabs has curated and owns one of the world’s largest biobanks, including over 610,000 saliva specimens from over 160,000 unique individuals; specimens included in this biobank may be appropriate for genetic and multi-omic discovery. These specimens, along with associated de-identified patient data, could allow QLabs to materially expand its research and development pipeline to include ADHD, Depression and Diabetes, among other medical conditions.
Quadrant Wastewater Solutions (“QWS”)
QWS provides communities throughout New York State and the New York State Department of Health (“NYSDOH”) with weekly wastewater surveillance reporting on the presence and relative abundance of the SARS-CoV-2 virus in wastewater sampled from municipal treatment facilities. QWS provides these services for approximately 90% of all counties in New York State. Additionally, QWS facilitates additional testing by the NYSDOH (including the phylogenetic classification of SARS-CoV-2 variants and genetic testing for other human pathogens) by providing extracted RNA from wastewater samples. Beginning in August 2023, QWS anticipates beginning in-house testing for additional human pathogens, including Norovirus, Hepatitis A, Flu A/B and RSV; concurrently, QWS will continue to provide extracted RNA to NYSDOH for the detection of Polio and potentially other human pathogens.
Autism Analytica : (“AA”)
AA develops commercial software designed to predict the type and frequency of services needed after a diagnosis of ASD and monitor a child’s progress through treatment over time. AA’s initial offerings will be comprised of (i) software to assist in clinical decision making, inclusive of ten parent/caregiver-completed, clinically validated, measures of a child’s strengths and challenges and the clinical compilation of these results (“Virtual IPM”), and (ii) an objective, clinical diagnostic aid which utilizes vision-tracking technology, proprietary stimuli. AA software is designed for use by clinicians diagnosing children with ASD and behavioral health specialists serving children with ASD.
Virtual IPM Platform
Virtual IPM is an assessment platform designed to inform evaluation and monitor progress in children with ASD and related developmental conditions. Our virtual IPM platform reduces the time and cost associated with evaluating ASD and other neurodevelopmental concerns while improving the quality of treatment through data driven recommendations to clinicians.
Thinking of Investing?
Reach out to our team directly using the link below and we'll be in touch shortly.Contact Us